scholarly journals Molecular typing of breast cancer in Northern Henan Province

2021 ◽  
Author(s):  
Hui Zhao ◽  
Haibin Ma ◽  
Bangze Chen ◽  
Yahui Li ◽  
Junzheng yang
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Molecular Typing ◽  
Ductal Carcinoma ◽  
Henan Province ◽  
Type I ◽  
Breast Cancer Patients ◽  
Ki 67 ◽  
Luminal B ◽  
Expression Rate

Objective: Investigating and analyzing the clinical features of breast cancer patients in Northern Henan Province, measuring expression of biomarkers (ER, PR, HER2 and Ki-67) and classified the molecular typing of breast cancer patients, to understand the molecular typing distribution and correlation between biomarkers of breast cancer patients in North Henan Province, which may provide the information for the local oncologist to make sound treatment plans. Methods: We collected the clinical data of breast cancer patients in Xinxiang Central Hospital from 2016 to 2021, those data was classified by gender and pathological types of breast cancer patients; and we also measured and analyzed the expression of breast cancer related biomarkers (ER, PR, HER2 and Ki-67) by immunohistochemistry, and based on expression of these biomarkers, the molecular typing of breast cancer were also classified. Results: 3210 cases breast cancer patients were collected in this study; there were 3205 female patients and 5 male patients, accounting for 99.84% and 0.16% in total breast cancer patients, respectively. Classification according to pathological conditions of breast cancer patients, there were 2761 cases patients with invasive ductal carcinoma, accounting for 86.01% in total breast cancer patients, and then mucinous adenocarcinoma (109/3210, 3.40%), lobular carcinoma (106/3210, 3.30%), ductal carcinoma in situ (75/3210, 2.34%), papillary carcinoma (61/3210, 1.90%), intraductal carcinoma (40/3210, 1.25%), myeloid carcinoma (27/3210, 0.84%); There were also including some rare breast cancer types including cribriform carcinoma (6/3210, 0.19%), lymph node metastasis (7/3210, 0.22%), occult breast carcinoma (5/3210, 0.14%), invasive carcinoma (5/3210, 0.14%), squamous cell carcinoma (3/3210, 0.09%), fibroadenoma (3/3210, 0.09%), pleomorphic carcinoma (2/3210, 0.06%). Classification according to molecular typing of breast cancer, the number of breast cancer patients with Luminal A type [ER(+)/PR(+) HER2(-)Ki67<14%] were 207 cases, accounting for 6.45% in total breast cancer patients, the number of breast cancer patients with Luminal B type I [ER(+)/PR(+) HER2(-)] were 243 cases, accounting for 7.57% in total breast cancer patients, the number of breast cancer patients with Luminal B type II [(ER(+)/PR(+)HER2(+) any Ki67] was 254 cases, accounting for 7.91% in total breast cancer patients, and the number of Triple-negative breast cancer (TNBC) were 390 cases, accounting for 12.15% in total breast cancer patients. The average expression rate of Ki-67 in ER (+) and/or PR (+) breast cancer patients was 20.39+27.33%, while the average expression rate of Ki-67 in ER(-)/PR(-) breast cancer patients was 36.35%+30.14%, and the difference between two patients was significant (p=0.0021); the average expression rate of Ki-67 in HER2 positive breast cancer patients was 23.01%+21.96%, the average expression rate of Ki-67 in HER2 negative breast cancer patients was 29.44%+24.16%, and there was no significant difference between the two groups (P=0.2589). The main treatment methods of breast cancer patients in Northern Henan Province were antitumor drugs and chemotherapy, the results showed that 87.29% patients were treated by chemotherapy; and high frequency anti-tumor drugs used for breast cancer treatment were Epirubicin (1527/3210, 47.57%)，Cyclophosphamide (1172/3210, 36.51%)，Paclitaxel (1141/3210，35.55%), Tamoxifen (912/3210, 28.41%). Conclusions: The main pathological type of breast cancer are invasive ductal carcinoma, and the main treatment methods of breast cancer patients in Northern Henan Province were antitumor drugs and chemotherapy. In the four kinds of molecular typing of breast cancer, the incidence rate of TNBC is highest compared with Luminal B type II[(ER(+)/PR(+)HER2(+) any Ki67], Luminal B type I [ER(+)/PR(+)HER2(-)] and Luminal A type [ER(+)/PR(+) HER2(-) Ki67<14%]; these results may provide some suggestions for the local oncologist.

The role of Ki-67 in molecular breast cancer classification.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 583-583
Author(s):  
George Stathopoulos ◽  
Nikolaos Malamos ◽  
Christos Markopoulos ◽  
Athanasios Polychronis ◽  
Sotirios Rigatos ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Triple Negative ◽  
Progesterone Receptors ◽  
Molecular Classification ◽  
Breast Cancer Patients ◽  
Luminal A ◽  
Ki 67 ◽  
Luminal B ◽  
Her 2

583 Background: The Ki-67 antigen was identified the involvement in early steps of polymerase I-dependent ribosomal RNA synthesis. Although it seems that the protein has an important function in cell division, its exact role is still obscure and there is little published work on its overall function. The aim of the present study is to evaluate the contribution of Ki-67 level in respect of tumor recurrence in molecular classified groups of breast cancer patients. Methods: Breast cancer tumor samples were examined for histological confirmation and for estrogen and progesterone receptors, c-erb-B2 expression, proliferation with Grade and Ki-67. Ki-67 was divided in percentage levels, up to 20 and higher than 20%. Immunohistochemistry and Fluorescence in situ hybridization is described for the results of ER, PR, c-erb-B2, Ki-67 biomarkers. Formaldehyde – fixed breast samples were paraffin wax embedded and processed for paraffin sections. The primary antibodies used were: The monoclinal antibody ID5 (M7047, Dakocytomation, Carpinteria, CA) for the detection of ER, the monoclonal anti-PR antibody 636 was used. For the detection of Ki-67 we used monoclonal mouse anti-human Ki-67 MIB-1. The patients molecular classification was Luminal A, Luminal B, Her-2 subtype and basal cell (triple negative). Results: 847 breast cancer patients were recruited. 291 were group as Luminal A, 228 as Luminal B, 221 Her-2 subtype and 107 triple negative. Follow-up was from 3 years to 15 years since diagnosis. It was found that in Luminal A patients, none had Ki-67 higher than 20% and the recurrence was in 10.65%. In Luminal B, the Ki-67 was higher than 20% in 61% of the patients and recurrence 23.68%. In Her-2 subtype >20% Ki-67 was 78.94%, recurrence 17.19%. In triple negative > 20% Ki-67 was in 68.75% and recurrence in 29.90% of the patients. Conclusions: The data presented here indicate that Ki-67 level may be considered as one of valuable biomarkers in breast cancer patients process and recurrence.

Prognostic subset of metastatic and non-metastatic luminal B breast cancer (LBBC) subtype based on Ki67 index.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e12570-e12570
Author(s):  
Lalnun Puii ◽  
Lalram Sangi ◽  
Hrishi Varayathu ◽  
Samuel Luke Koramati ◽  
Beulah Elsa Thomas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Disease ◽  
Ki67 Index ◽  
Breast Cancer Patients ◽  
Luminal A ◽  
Her2 Positive ◽  
Ki 67 ◽  
Luminal B ◽  
Therapeutic Implications ◽  
Significant Difference

e12570 Background: Gene expression profiling for breast cancer has classified ER positive subtype into luminal A and luminal B. Luminal B breast cancer (LBBC) have a higher proliferation and poorer prognosis than luminal A tumors. Ki-67 index is the commonly used proliferation marker in breast cancer; however Ki67 expression can also be used to identify a subset of patients among LB with a favorable prognosis. This study attempts to verify this subset of LBBC patients based on DFS and PFS in non-metastatic and metastatic patients respectively. Methods: We retrospectively analyzed 80 IDC breast cancer patients diagnosed in 2013-2016 with complete follow-up till January-2021. We defined LBBC as ER+, PR+ or PR- , HER2+ or HER2- with a Ki67 index >20%. PFS was considered as the endpoint in patients presenting with metastatic disease whereas DFS was used in non-metastatic disease. The cut-off for ki67 was calculated using an X-tile plot (version 3.6.1, Yale University) by dividing Ki67 data into two populations: low and high, with randomized 1:1 “training” and “validation” cohorts. Results: Median age was 51.5 years. 18.7% (n=15) presented with metastasis at the time of diagnosis and their overall median PFS was found to be 25.8 months. The incidence of HER2 positive LBBC was found to be 15% (n=12) and none of them were found to be presented with metastasis. Survival and frequency of various sub groups in our study are enlisted in the given table. We estimated a Ki67 cut-off of 30% in patients with upfront metastatic disease and PFS was found to be higher in <30% compared to a Ki67 index >30% (38.9 months vs 19.7 months, p-0.002). Overall median DFS was not achieved in non-metastatic group (Mean DFS: 64.7 months) where as a statistically significant difference was observed in the survival of HER2 positive (median DFS: 53.5 months, mean DFS: 50.9) than HER2 negative patients (median DFS not achieved, mean: 66.97 months) ( p-0.021). We obtained a Ki67 cut-off of 32% in non- metastatic group and mean DFS was found to be higher in Ki67<32% (69 months) compared to Ki67>32% (61.4 months), however it failed to exhibit a statistically significant relationship ( p-0.373). Conclusions: Our study indicates that a subset of patients exists within metastatic and non-metastatic LBBC with differing prognosis based on Ki67. Larger studies are further required to confirm the findings and therapeutic implications.[Table: see text]

scholarly journals The Value of Ultrasound Diagnosed Axillary Lymph Node in Avoiding Axillary Surgery in Early Breast Cancer Patients

2020 ◽  
Author(s):  
Na Liu ◽  
Liu Yang ◽  
Xinle Wang ◽  
Meiqi Wang ◽  
Ruoyang Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Axillary Lymph Node ◽  
Histological Grade ◽  
False Negative ◽  
Axillary Lymph ◽  
Breast Cancer Patients ◽  
Ki 67 ◽  
Axillary Surgery

Abstract Background: Axillary lymph node dissection can be avoided in early stage breast cancer patients with negative sentinel lymph node biopsy. However, the possibility of avoiding axillary surgery in patients without axillary lymph node metastasis (ALNM) by preoperative imaging is still under exploration. Thus, the objectives of this study were to investigate the high-risk factors of false negative of ALNM diagnosed by preoperative ultrasound (US) and to find out who could be avoided axillary surgery in the US negative ALNM patients.Methods: This study retrospectively analyzed 3,361 patients with primary early breast cancer diagnosed in the Breast Center of the Fourth Hospital of Hebei Medical University from January 2010 to December 2012. All patients had undergone routine preoperative US and then axillary lymph node dissected. This study investigated the clinicopathological features of axillary lymph node (ALN) negative patients diagnosed by preoperative US and its correlation with prognosis. The follow-up data for disease-free survival (DFS) and overall survival (OS) were obtained from 2,357 patients. Results: The sensitivity, specificity and accuracy of axillary US in this cohort were 66.24%, 76.62% and 73.87%. The proportion of patients in the false negative group was higher than that in true negative in the group of age < 50 years old (P = 0.002), tumor size > 2cm (P = 0.008), estrogen receptor (ER) positive (P = 0.005), progesterone receptor (PR) high expression (P = 0.007), nuclear-associated antigen Ki-67 (Ki-67) >20% (P = 0.030), visible vascular tumor thrombus (P < 0.001) and histological grade>2 (P < 0.001). Prognostic analysis of false negative and true negative ultrasonographic diagnosis of ALN metastasis: when ALNM was not found by preoperative ultrasound, there was no significant difference in patients with ALNM≤3 compared with patients without lymph node metastasis in patients of age ≥ 50 years old, tumor size ≤ 2cm, Ki-67 ≤ 20%, or histological grade ≤ 2. Conclusion: The surgery of ALN may be avoided for the preoperative US diagnosed ALNs negative in early breast cancer patients who had advanced age, small tumor size, low expression of Ki-67 and low histological grade.

Sign in / Sign up

Export Citation Format

Share Document